Bolt Biotherapeutics Inc <BOLT.OQ> expected to post a loss of 38 cents a share - Earnings Preview
Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected to show a fall in quarterly revenue when it reports results on March 19 (estimated) for the period ending December 31 2024
The Redwood City California-based company is expected to report a 62.2% decrease in revenue to $790 thousand from $2.09 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bolt Biotherapeutics Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $1.75, above its last closing price of $0.41.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.34 | -0.35 | -0.40 | Missed | -13.5 |
Jun. 30 2024 | -0.52 | -0.48 | -0.46 | Beat | 4.2 |
Mar. 31 2024 | -0.50 | -0.51 | -0.28 | Beat | 45.1 |
Dec. 31 2023 | -0.44 | -0.48 | -0.47 | Beat | 2.4 |
Sep. 30 2023 | -0.50 | -0.50 | -0.43 | Beat | 14 |
Jun. 30 2023 | -0.50 | -0.49 | -0.48 | Beat | 1.4 |
Mar. 31 2023 | -0.51 | -0.51 | -0.45 | Beat | 12.1 |
Dec. 31 2022 | -0.60 | -0.53 | Beat | 11.4 |
This summary was machine generated March 17 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
